Inuvo Reaffirms 25% Q2 YOY Growth Guidance and Completes 1:10 Reverse Stock Split

Stock Information for Asterias Biotherapeutics Inc. Common Series A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Asterias Biotherapeutics Inc. Common Series A

Inuvo Launches Ranger: AI Tool for Ad Quality and Compliance
Inuvo Introduces IntentPath for Next-Level Audience Visualization
Inuvo Reports Revenue of $22.6 Million in the Third Quarter 2025
Inuvo to Host Third Quarter 2025 Financial Results Conference Call on Thursday, November 6th at 4:15 P.M. ET
Inuvo to Present at the LD Micro Main Event XIX
Inuvo Appoints Rob Buchner as Chief Operating Officer to Accelerate Growth of IntentKey
Inuvo to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th-10th
Inuvo Posts 25% Growth in the Second Quarter 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.